Coffin-Siris syndrome

Was ist Coffin-Siris syndrome?

Coffin-Siris syndrome, auch bekannt als CSS oder 5te Ziffer syndrom, zeichnet sich durch grobe Gesichtszüge und eine Unterentwicklung des 5ten Fingers oder Zehs aus. Symptome kann von Person zu Person variieren syndrom.

Gesundheitszustände im Zusammenhang mit Coffin-Siris syndrome kann Anomalien der Augen, des Gehirns, des Herzens und der Nieren umfassen.

Syndrom Synonyme:
CSS

Was Genveränderungen verursachen Coffin-Siris syndrome?

Coffin-Siris syndrometritt aufgrund von Mutationen in den folgenden Genen auf: ARID1A, ARID1B, SMARCE4, SMARCB1, DPF2, SMARCE1. Es wird autosomal-dominant vererbt.

Bei autosomal-dominanter Vererbung ist nur ein Elternteil Träger der Genmutation, und sie haben eine Wahrscheinlichkeit von 50 %, sie an jedes ihrer Kinder weiterzugeben. Syndromes autosomal-dominant vererbt werden durch nur eine Kopie der Genmutation verursacht.

Gene, Standorte und Vererbungsmodi:
ARID1A, 1p36.11 - Autosomal dominant
ARID2, 1p36.11 - Autosomal dominant
SMARCB1, 22q11.23 - Autosomal dominant
SOX11, 2p25.2 - Autosomal dominant
SMARCA1, Xq25-q26 - Autosomal dominant
SMARCA4, 19p13.2 – autosomal dominant
SMARCA2, 9p24.3 - Autosomal dominant
SMARCE1, 17q21.2 - Autosomal dominant
ARID1B, 6q25.3 - Autosomal dominant

OMIM-Nummer - 135900 (Bitte überprüfen Sie die OMIM-Seite für aktualisierte Informationen)

Was sind die wichtigsten symptome von Coffin-Siris syndrome?

Coffin-Siris syndromeIst Hauptsache symptome umfassen, was oft als grobe Gesichtsmerkmale beschrieben wird - ein breiter Mund und eine breite Nase, dicke Lippen, ein flacher Nasenrücken und eine Kleinwüchsigkeit. Das syndrom ist gekennzeichnet durch übermäßigen Haarwuchs im Gesicht und am Körper, aber gleichzeitig durch spärlichen Haarwuchs auf der Kopfhaut.

Eine unterentwickelte 5te Ziffer an Hand oder Fuß ist die Hauptsache symptom. Andere symptome kann einen niedrigen Muskeltonus, Kleinwuchs, Atemwegsinfektionen und Gedeihstörungen im Säuglingsalter umfassen.

Entwicklungsverzögerungen und intellektuelle Behinderungen sind häufig, und Sprach- und Motorikverzögerungen sind häufig.

Wie wird jemand getestet? Coffin-Siris syndrome?

Die ersten Tests für Coffin-Siris syndrome kann mit einem Gesichtsanalyse-Screening beginnen, durch die FDNA Telehealth Telegenetik-Plattform, die die Schlüsselmarker der syndrom und skizzieren Sie die Notwendigkeit weiterer Tests. Es folgt ein Beratungsgespräch mit einem genetischen Berater und dann einem Genetiker. 

Basierend auf dieser klinischen Konsultation mit einem Genetiker werden die verschiedenen Optionen für Gentests geteilt und die Zustimmung für weitere Tests eingeholt.

Medizinische Informationen zu Coffin-Siris syndrome

AUTHOR(S):  Eline van der Sluijs, Samantha Schrier Vergano, Gijs Santen
KEYWORDS:  Intellectual disability, dysmorphic features, hypertrichosis, fifth finger hypoplasia

SYNDROME INFO:
SYNDROME NAME-
Coffin Siris Syndrome 
SYNDROME OMIM NUMBER-
135900 (ARID1B), 614607 (ARID1A), 614608 (SMARCB1), 614609 (SMARCA4), 616938 (SMARCE1), 617808 (ARID2)
OMIM LINK-
https://www.omim.org/entry/135900
 
OTHER LINKS
GeneReviews
https://www.ncbi.nlm.nih.gov/books/NBK131811/
Orphanet
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=1465

ALTERNATIVE NAMES-
Coffin-Siris syndrome; CSS
FIFTH DIGIT SYNDROME 

PHENOTYPIC SERIES-
Coffin-Siris syndrome 1
Coffin-Siris syndrome 2
Coffin-Siris syndrome 3
Coffin-Siris syndrome 4
Coffin-Siris syndrome 5
Coffin-Siris syndrome 6

DISEASE OVERVIEW:
Coffin Siris Syndrome (CSS) shows autosomal dominant inheritance and is classically characterized by intellectual disability, varying degrees of developmental and speech delay, feeding difficulties, distinct facial features, hypertrichosis and aplasia or hypoplasia of the distal phalanx of the fifth and/or additional fingers and nails. In most patients this syndrome is caused by a mutation in genes (ARID1B, ARID1A, SMARCB1, SMARCA4, SMARCE1, ARID2) encoding components of the BAF (mSWI/SNF) complex, which regulates gene expression through chromatin remodeling. In addition, some CSS patients have mutations in SOX11; SOX11 also influences gene expression since it is a transcriptional factor forming a cross-regulatory network downstream of the PAX6-BAF complex. Mutation in DPF2 have also been described in 8 individuals with a CSS-like phenotype.

MOLECULAR GENETICS:

ASSOCIATED GENE(S)-
ARID1B, ARID1A, SMARCB1, SMARCA4, SMARCE1, ARID2, SOX11 , DPF2

OMIM NUMBER(S)-
ARID1B (614556), ARID1A (603024), SMARCB1 (601607), SMARCA4 (603254), SMARCE1 (603111), ARID2 (609539), SOX11 (600898), DPF2 (601671)

GENE LOCATION(S)-
ARID1B: 6q25.3
ARID1A: 1p36.11
SMARCB1: 22q11.23
SMARCA4: 19p13.2
SMARCE1: 17.21.2
ARID2: 12q12
SOX11: 2p25.2
DPF2: 11q13.1

TYPE OF MUTATION(S)-
ARID1B: almost always truncating mutations or whole gene deletions, one de novo missense in CSS-like patient in literature. Several missense mutations have been reported in patients with isolated short stature.
ARID1A: all described mutations truncating, some are mosaic suggesting that full mutations either give another phenotype or are incompatible with life.
SMARCB1: missense mutations in exon 8/9
SMARCE1: missense mutations in HMG domain
SMARCA4: missense mutations in functional domains of the protein
ARID2: truncating mutations or deletions
SOX11: truncating mutations, deletions or missense variants in HMG DNA binding domain
DPF2: missense, frameshift and splice-site mutations (likely dominant-negative)

GENOTYPE/PHENOTYPE CORRELATION-
There appears to be significant overlap between patients with mutations in the aforementioned genes. In general, patients with mutations in SMARCE1, SMARCB1 or SMARCA4 have more congenital anomalies than patients with mutations in the other genes.

SYNDROME CHARACTERISTICS:
MODE(S) OF INHERITENCE-
Autosomal dominant 
PENETRANCE-
Appears to be complete: All published mutations are de novo or inherited from affected parents.
PREVALENCE-
ARID1B mutations are one of the most frequent causes of intellectual disability (up to 1% of patients). More than 200 patients with mutations in the BAF complex have been thus far described.
LIFE EXPECTANCY-
Due to assessment bias the number of known older patients with mutations in the BAF complex is low. There is currently no evidence for a reduced life expectancy.
AGE OF ONSET-
Congenital 
PRENATAL PESENTATION-
Agenesis of the corpus callosum may be detected prenatally.

KEY CLINICAL FEATURES/PHENOTYPES:
Abnormality of the face
Coarse facial features HP:0000280
Abnormality of the forehead HP:0000290
Depressed nasal bridge HP:0005280
Wide nose HP:0000445
Abnormality of the philtrum HP:0000288
Wide mouth HP:0000154
Thick lower lip vermilion HP:0000179
Abnormality of the hair
Hypertrichosis HP:0000998
Sparse scalp hair HP:0002209
Thick eyebrows HP:0000574
Abnormality of the voice
Abnormality of the skeletal system
Scoliosis HP:0002650
Abnormality of the ear
Abnormality of the pinna HP:0000377
Abnormality of limbs
Aplasia/Hypoplasia of the distal phalanx of the 5th finger HP:0009239
Aplasia/Hypoplasia of the distal phalanx of the 5th toe HP:0100371
Aplasia/Hypoplasia of the distal phalanges of the hand HP:0009835
Small nails HP:0001792
Abnormality of the digestive system HP:0025032
Feeding difficulties HP:0011968
Constipation HP:0002019
Abnormality of the nervous system
Agenesis of the corpus callosum HP:0001274
(Abnormality of prenatal development or birth)
Abnormality of the genitourinary system
Cryptorchidism HP:0000028
Abnormality of the kidney HP:0000077
Abnormality of the musculature
Muscular hypotonia HP:0001252
(Neoplasm)
Growth abnormality
Short stature HP:0004322
(Abnormality of the endocrine system)
Abnormality of the respiratory system
Laryngomalacia HP:0001601
Abnormality of the cardiovascular system
Abnormality of the cardiac septa HP:0001671
Abnormality of the heart valves HP:0001654
Abnormality of the eye
Myopia HP:0000545
(Abnormality of the immune system)
Neurodevelopmental delay HP:0012758
Delayed speech and language development HP:0000750
Motor delay HP:0001270

CLINICAL DESCRIPTION (GENERAL):
In general all CSS patients have developmental and speech delay and intellectual disability, developmental and speech delay, distinct facial features (see CLINICAL DESCRIPTION (BODY SYSTEMS)) and hypertrichosis. Most patients have aplasia or hypoplasia of the distal phalanx of the 5th and/or additional fingers and nails. Some patients have additional congenital anomalies, such as brain, cardiac or renal anomalies

CLINICAL DESCRIPTION (BODY SYSTEMS):
Growth and development
Most patients have a height below the 50th percentile and (± 20% below the 5th percentile). Likewise, development is delayed in patients. In most patients speech is impaired, with no speech development in around 20% of patients. Scoliosis is found in 20-30% of patients.

Dysmorphic features
Features characteristic for CSS patients are coarse facial features, sparse scalp hair, low anterior hairline, thick eyebrows, flat nasal bridge, thick alae nasi, large mouth and thick lower lip vermillion.

Skeletal abnormalities
Scoliosis is found in 20-30% of patients.

Neurological features
Intellectual disability is reported in (almost) all patients. Hypotonia (±80%) and seizures (20-50%) are seen in a considerable proportion of patients. A variety of brain anomalies have been reported in CSS patients, of which agenesis of the corpus callosum (24-41%) is the most frequent. Other brain anomalies are Dandy Walker, gyri simplification, mega cisterna magna, colpocephaly and delayed myelinization.

Cardiac anomalies
A subset of patients have cardiac and/or renal anomalies. Cardiac anomalies include atrial and/or ventricular septal defect, patent ductus arteriosus and tetralogy of Fallot.

Renal and genital anomalies
Renal anomalies include horseshoe kidney, hydronephrotic kidney and urolithiasis. Cryptorchidism is frequently found.

Visual and hearing impairment
Impairment of hearing and/or vision is prevalent among CSS patients. The prevalence of both impairments seem to differ between genes, but in general it appears that vision impairment is slightly more prevalent than hearing impairment. Vision impairment consists mostly of myopia (e.g. 20-30% ARID1B patients have myopia) and hearing problems are in most cases either congenital or related to associated with recurrent upper respiratory tract infections.

Gastrointestinal anomalies
Gastrointestinal anomalies consist mainly of feeding and swallowing difficulties, for which a subset of patients needs tube feeding. Other reported anomalies are constipation, gastroesophageal reflux and pyloric stenosis.

Endocrinological abnormalities
Several endocrinological abnormalities have been found in CSS patients, but it is still unclear whether these are part of the spectrum. Hyperinsulinism has been described in two patients with ARID1B mutations and diabetes mellitus in a patient with ARID1A mutation.

Cancer
Some CSS patients have been reported with malignancies (ARID1B - one patient with papillary thyroid cancer, ARID1A - one with hepatoblastoma and 1 with ALL, a SMARCB1 - one patient with schwannomatosis). An increased cancer risk cannot be ruled out for these patients and therefore the additional value of monitoring potential neoplasm development is not determined yet. A screening program is at present not warranted.

ARID1B
ARID1B patients (which constitute 51-75%1-3 of CSS patients with a known genetic cause) are also characterized by laryngomalacia, agenesis of the corpus callosum, myopia and cryptorchidism. (To be published) Both seizures and scoliosis occur in ±25% of patients.

ARID1A
The main clinical features of individuals with an ARID1A mutation can differ fromare mild to severe intellectual disability with internal complications. Agenesis of the corpus callosum is a frequently reported CNS anomaly among ARID1A patients. Behavioral abnormalities are reported in ±50% of patients. Some individuals also had serious medical complications (e.g., aspiration pneumonia, seizures) leading to death.

SMARCB1
Individuals with a pathogenic variant in SMARCB1 typically have a more severely affected phenotype and all have growth impairment, usually mild prenatally and moderate to severe postnatally, with sucking/feeding difficulty. Structural CNS abnormalities with hypotonia and seizures are typical findings accompanied by severe developmental delay/intellectual disability; individuals are typically nonverbal. Scoliosis is a typical skeletal finding. Some individuals may walk independently. Gastrointestinal complications and hernia as well as cardiovascular and genitourinary complications are common.

SMARCA4
About half of the patients have severe developmental delay or ID, and occasionally (20–30%) speak no words. Growth impairment is mild prenatally and mild‐to‐moderate postnatally, and difficulty in sucking/feeding is almost always observed. Facial coarseness is evident and a pointed chin in older ages is noted. Internal organs are impaired in most. Patients usually have hypotonia, structural CNS abnormalities, and behavioral abnormalities.
SMARCA4 mutations have been identified in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) tumors. These tumors are rare and usually found in young females. In general, the SMARCA4 variants in these tumors are truncating, while in CSS patients missense or in-frame deletions have been identified. An increased cancer risk in Coffin-Siris syndrome patients with a mutation in SMARCA4 has not been proven.

SMARCE1
Individuals with pathogenic SMARCE1 variants tend to have severe intellectual disability, typical facial gestalt, and hypoplastic or absent fifth finger- and toenails associated with hypoplasia of other nails. The hands are characterized by long and slender fingers. Individuals are typically small for gestational age and have postnatal short stature and severe microcephaly, complex congenital heart defects and feeding difficulties.

ARID2
Most individuals with ARID2 pathogenic variants demonstrate intellectual disability, hypotonia, and behavioral anomalies. Birth defects are not common. Several individuals have demonstrated very mild hypoplasia of the fifth fingernails and hypoplasia of the fifth toenails. Individuals with ARID2 pathogenic variants share some facial features with each other: coarse features, frontal bossing and high forehead, narrow palpebral fissures, flat nasal bridge, slightly broad nose with upturned nasal tip and thick, anteverted alae nasi, prominent philtrum, and a large mouth with a thick lower vermilion.

SOX11
Individuals display mild to severe intellectual and developmental delay, along with fifth digit nail and distal phalangeal hypoplasia. Neurodevelopmental abnormalities tend to be more prevalent than organ-system or physical complications.

DPF2
Eight patients had thus far been described, with a phenotype consisting of ‘coarse facial features, global developmental delay, intellectual disability, speech impairment, and hypoplasia of fingernails and toenails.

SURVEILLANCE:
- Regular evaluation by a developmental pediatrician to assess developmental progress and therapeutic and educational interventions
- Annual follow up with a gastroenterologist and feeding specialists as needed to monitor feeding and weight gain
- Regular follow up of ophthalmologic and/or audiologic abnormalities
Presently a tumor screening program is not warranted, because of the rarity of tumors in CSS. It may be considered to screen SMARCB1 patients for schwannoma’s from 18 years onwards.

MANAGEMENT AND TREATMENT:
At time of diagnosis:
- Consultation with a clinical geneticist and/or genetic counselor
- Neurologic and/or developmental examination to record developmental milestones and identify neurologic symptoms or deficits
- Evaluation for occupational, speech, or physical therapy as needed
- Growth should be monitored closely. Probands should have regular evaluations with gastroenterology or feeding specialists to monitor feeding and weight gain. Nutritional supplementation or G‐tube placement may be necessary to facilitate weight gain.
- Ophthalmologic examination, including a dilated fundus examination and visual acuity
- Audiology evaluation with auditory brain stem response testing and otoacoustic emission testing to assess for hearing loss
- Cardiology evaluations, including an echocardiogram should be considered to assess for structural cardiac anomalies.
- Given the prevalence of both structural kidney and genitourinary anomalies, a renal ultrasound should be considered.
Treatment of manifestations:
- Occupational, physical, and/or speech therapies to optimize developmental outcomes
- Feeding therapy, nutritional supplementation, and/or gastrostomy tube placement as needed to meet nutritional needs
- Spectacles as needed to correct refractive errors and surgery as needed for strabismus and/or ptosis
- Hearing aids as needed

PATIENT ORGANIZATIONS:
If you have identified patients with mutations in one of the CSS-associated genes we invite you to contact one of the gene-moderators of humandiseasegenes.nl to submit your patient data into an online gene-specific database, which aims to gather more knowledge to improve patients care.
http://www.humandiseasegenes.nl
ARID1B: www.humandiseasegenes.nl/arid1b
ARID1A: www.humandiseasegenes.nl/arid1a 
SMARCA4: www.humandiseasegenes.nl/smarca4 

Coffin-Siris syndrome/BAF Pathway Registry - if you have a patient with CSS or mutations in the BAF Pathway, please contact Dr. Samantha Vergano at [email protected] for information on registry enrollment.

Coffin-Siris syndrome Foundation - http://www.coffinsiris.org

KEY PUBLICATIONS:
Coffin Siris Syndrome:
Schrier Vergano S, Santen G, Wieczorek D, Wollnik B, Matsumoto N, Deardorff MA. Coffin-Siris syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews(R). Seattle (WA)1993.
Vergano SS, Deardorff MA. Clinical features, diagnostic criteria, and management of Coffin-Siris syndrome. Am J Med Genet C Semin Med Genet. 2014;166C(3):252-256. PMID: 25169447.
Santen GW, Aten E, Vulto-van Silfhout AT, et al. Coffin-Siris syndrome and the BAF complex: genotype-phenotype study in 63 patients. Hum Mutat. 2013;34(11):1519-1528. PMID: 23929686.
Wieczorek D, Bogershausen N, Beleggia F, et al. A comprehensive molecular study on Coffin-Siris and Nicolaides-Baraitser syndromes identifies a broad molecular and clinical spectrum converging on altered chromatin remodeling. Hum Mol Genet. 2013;22(25):5121-5135. PMID: 23906836.
Tsurusaki Y, Okamoto N, Ohashi H, et al. Coffin-Siris syndrome is a SWI/SNF complex disorder. Clin Genet. 2014;85(6):548-554. PMID: 23815551.
Kosho T, Okamoto N, Coffin-Siris syndrome International C. Genotype-phenotype correlation of Coffin-Siris syndrome caused by mutations in SMARCB1, SMARCA4, SMARCE1, and ARID1A. Am J Med Genet C Semin Med Genet. 2014;166C(3):262-275. PMID: 25168959.
Kosho T, Miyake N, Carey JC. Coffin-Siris syndrome and related disorders involving components of the BAF (mSWI/SNF) complex: historical review and recent advances using next generation sequencing. Am J Med Genet C Semin Med Genet. 2014;166C(3):241-251. PMID: 25169878.

Gene-specific:
ARID1B
Santen GW, Clayton-Smith J, consortium ABC. The ARID1B phenotype: what we have learned so far. Am J Med Genet C Semin Med Genet. 2014;166C(3):276-289. PMID: 25169814.
ARID1A
Duplication
Bidart M, El Atifi M, Miladi S, et al. Microduplication of the ARID1A gene causes intellectual disability with recognizable syndromic features. Genet Med. 2017;19(6):701-710. PMID: 27906199.
SMARCB1
SMARCA4
Errichiello E, Mustafa N, Vetro A, et al. SMARCA4 inactivating mutations cause concomitant Coffin-Siris syndrome, microphthalmia and small-cell carcinoma of the ovary hypercalcaemic type. J Pathol. 2017;243(1):9-15. PMID: 28608987.
SMARCE1
Zarate YA, Bhoj E, Kaylor J, et al. SMARCE1, a rare cause of Coffin-Siris syndrome: Clinical description of three additional cases. Am J Med Genet A. 2016;170(8):1967-1973. PMID: 27264197.
ARID2
Bramswig NC, Caluseriu O, Ludecke HJ, et al. Heterozygosity for ARID2 loss-of-function mutations in individuals with a Coffin-Siris syndrome-like phenotype. Hum Genet. 2017;136(3):297-305. PMID: 28124119.
Van Paemel R, De Bruyne P, van der Straaten S, et al. Confirmation of an ARID2 defect in SWI/SNF-related intellectual disability. Am J Med Genet A. 2017;173(11):3104-3108. PMID: 28884947.
SOX11
Tsurusaki Y, Koshimizu E, Ohashi H, et al. De novo SOX11 mutations cause Coffin-Siris syndrome. Nat Commun. 2014;5:4011. PMID: 24886874.
Hempel A, Pagnamenta AT, Blyth M, et al. Deletions and de novo mutations of SOX11 are associated with a neurodevelopmental disorder with features of Coffin-Siris syndrome. J Med Genet. 2016;53(3):152-162. PMID: 26543203.
Okamoto N, Ehara E, Tsurusaki Y, Miyake N, Matsumoto N. Coffin-Siris syndrome and cardiac anomaly with a novel SOX11 mutation. Congenit Anom (Kyoto). 2017. PMID: 28787104.
DPF2
Vasileiou G, Vergarajauregui S, Endele S, et al. Mutations in the BAF-Complex Subunit DPF2 Are Associated with Coffin-Siris syndrome. Am J Hum Genet. 2018;102(3):468-479. PMID: 29429572.

* This information is courtesy of the L M D.
If you find a mistake or would like to contribute additional information, please email us at: [email protected]

Erhalten Sie eine schnellere und genauere Genetische Diagnostik!

Mehr als 250,000 Patienten erfolgreich analysiert!
Warten Sie nicht Jahre auf eine Diagnose. Handeln Sie jetzt und sparen Sie wertvolle Zeit.

Los geht's!

"Unser Weg zu einer Diagnose seltener Krankheiten war eine 5 -jährige Reise, die ich nur als Versuch beschreiben kann, einen Roadtrip ohne Karte zu unternehmen. Wir kannten unseren Ausgangspunkt nicht. Wir kannten unser Ziel nicht. Jetzt haben wir Hoffnung. "

Bild

Paula und Bobby
Eltern von Lillie

Was ist FDNA Telehealth?

FDNA Telehealth ist ein führendes Unternehmen für digitale Gesundheit, das einen schnelleren Zugang zu genauen genetischen Analysen bietet.

Mit einer von führenden Genetikern empfohlenen Krankenhaustechnologie verbindet unsere einzigartige Plattform Patienten mit Genexperten, um ihre dringendsten Fragen zu beantworten und eventuelle Bedenken hinsichtlich ihrer Symptome zu klären.

Vorteile von FDNA Telehealth

FDNA-Symbol

Credibility

Unsere Plattform wird derzeit von über 70% der Genetiker verwendet und wurde zur Diagnose von über 250,000 Patienten weltweit eingesetzt.

FDNA-Symbol

Barrierefreiheit

FDNA Telehealth bietet innerhalb von Minuten eine Gesichtsanalyse und ein Screening, gefolgt von einem schnellen Zugang zu genetischen Beratern und Genetikern.

FDNA-Symbol

Benutzerfreundlichkeit

Unser nahtloser Prozess beginnt mit einer ersten Online-Diagnose durch einen genetischen Berater, gefolgt von Konsultationen mit Genetikern und Gentests.

FDNA-Symbol

Genauigkeit & Präzision

Erweiterte Funktionen und Technologien für künstliche Intelligenz (KI) mit einer Genauigkeitsrate von 90% für eine genauere genetische analyse.

FDNA-Symbol

Preis-Leistungs-Verhältnis

Schnellerer Zugang zu genetischen Beratern, Genetikern, Gentests und einer Diagnose. Falls erforderlich, innerhalb von 24 Stunden. Sparen Sie Zeit und Geld.

FDNA-Symbol

Privatsphäre & Sicherheit

Wir garantieren den größtmöglichen Schutz aller Bilder und Patienteninformationen. Ihre Daten sind immer sicher und verschlüsselt.

FDNA Telehealth kann Sie einer Diagnose näher bringen.
Vereinbaren Sie innerhalb von 72 Stunden ein Online-Treffen zur genetischen Beratung!

EspañolDeutschPortuguêsFrançaisEnglish